Chelator-Free Copper-64-Incorporated Iron Oxide Nanoparticles for PET/MR Imaging: Improved Radiocopper Stability and Cell Viability

Jang, Hye Min; Jung, Myung Hun; Lee, Jae Sang; Lee, Jun Sig; Lim, In Chul; Im, Hyunsik; Kim, Sang Wook; Kang, Shin‐Woong; Cho, Won-Je; Park, Jun Kue

doi:10.3390/nano12162791

Cited by 5 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the historical focus on T 2 contrast in IONP imaging, it is unsurprising that the same trend continues when IONPs are combined with radioisotopes. There is a substantial list of examples using iron oxide nanomaterials for T 2 -weighted PET/MRI imaging. − The incorporation of a radioisotope into the IONP considerably enhances the diagnostic capabilities of the probe; however, the utilization of T 2 contrast faces the same challenges that we have previously demonstrated in relation to the MRI part of the imaging. However, the use of IONP for T 1 could be a complication of the synthetic protocol.…”

Section: Iron Oxide Nanomaterials In Dual Nuclear Imaging–t 1-weighte...mentioning

confidence: 98%

Radiolabeled Iron Oxide Nanomaterials for Multimodal Nuclear Imaging and Positive Contrast Magnetic Resonance Imaging (MRI): A Review

Pellico,

Ruiz-Cabello,

Herranz

2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Iron oxide nanoparticles (IONP) have been hailed as potential game-changers in biomedical imaging owing to their biocompatibility and size-dependent properties. One area where IONP has shown particular promise is magnetic resonance imaging (MRI), which traditionally uses superparamagnetic nanomaterials to produce negative contrast that darkens the tissues where nanoparticles accumulates. Unfortunately, this hypointense signal is a major drawback for clinical applications because it can make it difficult to identify the accumulated probes. As a result, researchers are exploring alternative options that can incorporate the advantages of IONP while also possessing valuable properties for molecular imaging. To achieve this goal, the most effective method involves not only utilizing positive contrast in MRI applications but also combining IONP with the unparalleled sensitivity of nuclear imaging techniques, for example, using radioisotopes to create PET/(T 1)MRI multimodal probes. To create such probes, various factors must be considered, including the radiolabeling strategy employed and overall complexity of the final nanoprobe. These nanoradiomaterials offer novel possibilities that span beyond the molecular imaging field, showing potential for the development of radiopharmaceuticals and theranostics.

show abstract

Section: Iron Oxide Nanomaterials In Dual Nuclear Imaging–t 1-weighte...mentioning

confidence: 98%

Radiolabeled Iron Oxide Nanomaterials for Multimodal Nuclear Imaging and Positive Contrast Magnetic Resonance Imaging (MRI): A Review

Pellico,

Ruiz-Cabello,

Herranz

2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…IO nanoparticles with 64 Cu were found to act as a contrast agent for PET imaging and function effectively as a T2 MRI nanoprobe due to their favorable r2/r1 ratio. Incorporating 64 Cu at the core of core-shell-structured IO NPs demonstrated excellent in-vivo stability, offering valuable insights for designing PET-MRI contrast agents 179 . The initial version of a chelator called THPMe, which is made up of tris(1,6-dimethyl-3-hydroxypyridin-4-one) and designed explicitly for gallium-68 ( 68 Ga), has demonstrated significant potential in quickly and effectively labeling PET radiopharmaceuticals through kit-based methods.…”

Section: The Applications Of Iron Chelators In Pet/ct (Positron Emiss...mentioning

confidence: 99%

Iron chelators: as therapeutic agents in diseases

Salimi,

Afsharinasab,

Rostami

et al. 2024

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

The concentration of iron is tightly regulated, making it an essential element. Various cellular processes in the body rely on iron, such as oxygen sensing, oxygen transport, electron transfer, and DNA synthesis. Iron excess can be toxic because it participates in redox reactions that catalyze the production of reactive oxygen species (ROS) and elevate oxidative stress. Iron chelators are chemically diverse; they can coordinate six ligands in an octagonal sequence. Because of the ability of chelators to trap essential metals, including iron, they may involve in diseases caused by oxidative stress, such as infectious diseases, cardiovascular diseases, neurodegenerative diseases, and cancer. Iron chelating agents, by tightly binding to iron, prohibit it from functioning as a catalyst in redox reactions and transfer iron and excrete it from the body. Thus, using iron chelators as therapeutic agents has received increasing consideration. This review investigates the function of various iron chelators in treating ‎iron overload in different clinical conditions.

show abstract

“…Iron oxide nanoparticles (IONs) radiolabeled with 68 Ga and 177 Lu could be used as potential agents for positron emission tomography (PET) for diagnosis and cancer therapy [ 139 ]. Chelator-free copper-64 incorporated with IONs showed good in vivo stability and could be used as a contrast agent for PET/MRI [ 140 ].…”

Section: Nanoparticle-based Therapeutic Strategies For Enhanced Pdac ...mentioning

confidence: 99%

Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy

2022

View full text Add to dashboard Cite

Immunotherapy has dramatically changed prognosis for patients with malignant tumors. However, as a non-immunogenic tumor, pancreatic ductal adenocarcinoma (PDAC) has a low response to immunotherapy. Factors that contribute to the inefficiency of PDAC immunotherapy include the tumor microenvironment (TME) and its dense stroma, which acts as a barrier for drug delivery and immune cell infiltration. Recent studies have shown that nanoparticle-based therapeutic strategies have more promising applications in improving drug delivery and reversing the immunosuppressive TME for PDAC. Therefore, nanomaterial-based therapeutic approaches are expected to enhance the effectiveness of immunotherapy and improve prognosis of patients with PDAC. Here, we outline the status and dilemma of PDAC immunotherapy, and summarize the latest advances in nanoparticle-based treatment strategies to enhance the efficacy of PDAC immunotherapy.

show abstract

Chelator-Free Copper-64-Incorporated Iron Oxide Nanoparticles for PET/MR Imaging: Improved Radiocopper Stability and Cell Viability

Cited by 5 publications

References 37 publications

Radiolabeled Iron Oxide Nanomaterials for Multimodal Nuclear Imaging and Positive Contrast Magnetic Resonance Imaging (MRI): A Review

Radiolabeled Iron Oxide Nanomaterials for Multimodal Nuclear Imaging and Positive Contrast Magnetic Resonance Imaging (MRI): A Review

Iron chelators: as therapeutic agents in diseases

Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy

Contact Info

Product

Resources

About